Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 5, 2015, Pages 743-750.e1

  Casale, Thomas B ^a   Bernstein, Jonathan A ^b   Maurer, Marcus ^c   Saini, Sarbjit S ^d   Trzaskoma, Benjamin ^e   Chen, Hubert ^e   Grattan, Clive E ^f   Gimenéz Arnau, Ana ^g   Kaplan, Allen P ^h   Rosén, Karin ^e  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

^e GENENTECH INC   (United States)

^f NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antihistamine; Chronic idiopathic; Chronic spontaneous; Hive; Itch; Omalizumab; Pruritus; Urticaria; Wheal

Indexed keywords

OMALIZUMAB; PLACEBO; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC URTICARIA; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEMORRHOID; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PELVIS ABSCESS; PNEUMONIA; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL DISEASE; RHINOPHARYNGITIS; SINUSITIS; SKIN DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; UTERINE CERVIX DYSPLASIA; VIRAL UPPER RESPIRATORY TRACT INFECTION; ANALYSIS OF VARIANCE; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DOSE CALCULATION; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; URTICARIA;

ADULT; ANALYSIS OF VARIANCE; CHRONIC DISEASE; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H1 ANTAGONISTS; HISTAMINE H2 ANTAGONISTS; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; OMALIZUMAB; RECURRENCE; TREATMENT OUTCOME; URTICARIA;

EID: 84941259613     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.04.015     Document Type: Article

References (21)

1. Zuberbier T., Aberer W., Asero R., Bindslev-Jensen C., Brzoza Z., Canonica G.W., et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014, 69:868-887.
2. Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2007, 32:34-38.
3. Maurer M., Altrichter S., Bieber T., Biedermann T., Bräutigam M., Seyfried S., et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011, 128:202-209.e5.
4. Staevska M., Popov T.A., Kralimarkova T., Lazarova C., Kraeva S., Popova D., et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010, 125:676-682.
5. Khan D.A. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. J Allergy Clin Immunol Pract 2013, 1:433-440.e1.
6. Urgert M.C., van den Elzen M.T., Knulst A.C., Fedorowicz Z., van Zuuren E.J. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol 2015, http://dx.doi.org/10.1111/bjd.13845.
7. Xolair (omalizumab) prescribing information; 2014. Available from: Accessed May 27, 2015. http://www.gene.com/gene/products/information/pdf/xolair-prescribing.pdf.
8. Summary of product characteristics (omalizumab [Xolair]); 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf.
9. Saini S.S., Bindslev-Jensen C., Maurer M., Grob J.J., Bulbul Baskan E., Bradley M.S., et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015, 135:67-75.
10. Maurer M., Rosen K., Hsieh H.J., Saini S., Grattan C., Gimenéz-Arnau A., et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013, 368:924-935.
11. Kaplan A., Ledford D., Ashby M., Canvin J., Zazzali J.L., Conner E., et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013, 132:101-109.
12. Mathias S.D., Crosby R.D., Zazzali J.L., Maurer M., Saini S.S. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2012, 108:20-24.
13. Sampson H.A., Munoz-Furlong A., Campbell R.L., Adkinson N.F., Bock S.A., Branum A., et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 117:391-397.
14. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-190.
15. Soler M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254-261.
16. Long A., Rahmaoui A., Rothman K.J., Guinan E., Eisner M., Bradley M.S., et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014, 134:560-567.e4.
17. Long A.A., Fish J.E., Rahmaoui A., Miller M.K., Bradley M.S., Taki H.N., et al. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol 2009, 103:212-219.
18. Hanania N.A., Alpan O., Hamilos D.L., Condemi J.J., Reyes-Rivera I., Zhu J., et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011, 154:573-582.
19. Lundberg L., Johannesson M., Silverdahl M., Hermansson C., Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000, 80:430-434.
20. Norlin J.M., Steen Carlsson K., Persson U., Schmitt-Egenolf M. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol 2012, 166:797-802.
21. Bernstein J.A., Lang D.M., Khan D.A., Craig T., Dreyfus D., Hsieh F., et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014, 133:1270-1277.